176 related articles for article (PubMed ID: 29505590)
21. Varicella zoster and fever rash surveillance in Lao People's Democratic Republic.
Nouanthong P; Hübschen JM; Billamay S; Mongkhoune S; Vilivong K; Khounvisith V; Sinner R; Grandadam M; Phonekeo D; Black AP; Muller CP
BMC Infect Dis; 2019 May; 19(1):392. PubMed ID: 31068140
[TBL] [Abstract][Full Text] [Related]
22. Genotypic analysis of varicella-zoster virus and its seroprevalence in Finland.
Koskiniemi M; Lappalainen M; Schmid DS; Rubtcova E; Loparev VN
Clin Vaccine Immunol; 2007 Sep; 14(9):1057-61. PubMed ID: 17626161
[TBL] [Abstract][Full Text] [Related]
23. Live Attenuated Zoster Vaccine Boosts Varicella Zoster Virus (VZV)-Specific Humoral Responses Systemically and at the Cervicovaginal Mucosa of Kenyan VZV-Seropositive Women.
Perciani CT; Sekhon M; Hundal S; Farah B; Ostrowski MA; Anzala AO; McKinnon LR; Jaoko W; MacDonald KS;
J Infect Dis; 2018 Sep; 218(8):1210-1218. PubMed ID: 29800309
[TBL] [Abstract][Full Text] [Related]
24. Seroepidemiology of varicella-zoster virus and reliability of varicella history in Turkish children, adolescents and adults.
Koturoglu G; Kurugol Z; Turkoglu E
Paediatr Perinat Epidemiol; 2011 Jul; 25(4):388-93. PubMed ID: 21649681
[TBL] [Abstract][Full Text] [Related]
25. Seroprevalence of antibodies against varicella zoster virus and rubella virus among newly recruited expatriate healthcare workers: a cross-sectional study.
Shady I
BMJ Open; 2018 Mar; 8(3):e019339. PubMed ID: 29567844
[TBL] [Abstract][Full Text] [Related]
26. Integrating Alternative Social Value Judgments Into Cost-Effectiveness Analysis of Vaccines: An Application to Varicella-Zoster Virus Vaccination.
Luyten J; van Hoek AJ
Value Health; 2021 Jan; 24(1):41-49. PubMed ID: 33431152
[TBL] [Abstract][Full Text] [Related]
27. Varicella seroepidemiology in United States air force recruits: A retrospective cohort study comparing immunogenicity of varicella vaccination and natural infection.
Duncan JR; Witkop CT; Webber BJ; Costello AA
Vaccine; 2017 Apr; 35(18):2351-2357. PubMed ID: 28359621
[TBL] [Abstract][Full Text] [Related]
28. Varicella Zoster Virus: A Common Cause of Stroke in Children and Adults.
Amlie-Lefond C; Gilden D
J Stroke Cerebrovasc Dis; 2016 Jul; 25(7):1561-1569. PubMed ID: 27138380
[TBL] [Abstract][Full Text] [Related]
29. Changing seroprevalence of varicella zoster virus infection in a tropical city state, Singapore.
Fatha N; Ang LW; Goh KT
Int J Infect Dis; 2014 May; 22():73-7. PubMed ID: 24269652
[TBL] [Abstract][Full Text] [Related]
30. Distribution of Health Effects and Cost-effectiveness of Varicella Vaccination are Shaped by the Impact on Herpes Zoster.
van Lier A; Lugnér A; Opstelten W; Jochemsen P; Wallinga J; Schellevis F; Sanders E; de Melker H; van Boven M
EBioMedicine; 2015 Oct; 2(10):1494-9. PubMed ID: 26629544
[TBL] [Abstract][Full Text] [Related]
31. Declining seroprevalence of hepatitis A in Vojvodina, Serbia.
Medić S; Anastassopoulou C; Milošević V; Dragnić N; Rajčević S; Ristić M; Petrović V
PLoS One; 2019; 14(6):e0217176. PubMed ID: 31163046
[TBL] [Abstract][Full Text] [Related]
32. Analysis of factors associated with varicella-zoster virus susceptibility among children 0-12 years old in Taiwan.
Chang CK; Tan HF; Tseng HF; Lin CC
Med Mal Infect; 2007 Apr; 37(4):222-8. PubMed ID: 17368781
[TBL] [Abstract][Full Text] [Related]
33. Estimating the basic reproductive number of varicella in South Korea incorporating social contact patterns and seroprevalence.
Lee T; Suh J; Choi JK; Lee J; Park SH
Hum Vaccin Immunother; 2021 Aug; 17(8):2488-2493. PubMed ID: 33829948
[TBL] [Abstract][Full Text] [Related]
34. Projections of zoster incidence in Australia based on demographic and transmission models of varicella-zoster virus infection.
Costantino V; Gidding HF; Wood JG
Vaccine; 2017 Dec; 35(48 Pt B):6737-6742. PubMed ID: 29050801
[TBL] [Abstract][Full Text] [Related]
35. Seroprevalence survey for Varicella among healthcare workers and medical students in Italy.
Balbi O; Baldi S; Rizza S; Pietroiusti A; Perrone S; Coppeta L
Hum Vaccin Immunother; 2021 Feb; 17(2):372-376. PubMed ID: 32643520
[TBL] [Abstract][Full Text] [Related]
36. Myths and Misconceptions: Varicella-Zoster Virus Exposure, Infection Risks, Complications, and Treatments.
Newman AM; Jhaveri R
Clin Ther; 2019 Sep; 41(9):1816-1822. PubMed ID: 31326126
[TBL] [Abstract][Full Text] [Related]
37. The social contact hypothesis under the assumption of endemic equilibrium: Elucidating the transmission potential of VZV in Europe.
Santermans E; Goeyvaerts N; Melegaro A; Edmunds WJ; Faes C; Aerts M; Beutels P; Hens N
Epidemics; 2015 Jun; 11():14-23. PubMed ID: 25979278
[TBL] [Abstract][Full Text] [Related]
38. The cost-effectiveness of varicella and combined varicella and herpes zoster vaccination programmes in the United Kingdom.
van Hoek AJ; Melegaro A; Gay N; Bilcke J; Edmunds WJ
Vaccine; 2012 Feb; 30(6):1225-34. PubMed ID: 22119592
[TBL] [Abstract][Full Text] [Related]
39. Seroprevalence of varicella-zoster virus in Korea.
Choi WS; Noh JY; Huh JY; Jo YM; Lee J; Song JY; Kim WJ; Cheong HJ
J Med Virol; 2010 Dec; 82(12):2123-6. PubMed ID: 20981803
[TBL] [Abstract][Full Text] [Related]
40. The epidemiology of varicella and herpes zoster in The Netherlands: implications for varicella zoster virus vaccination.
de Melker H; Berbers G; Hahné S; Rümke H; van den Hof S; de Wit A; Boot H
Vaccine; 2006 May; 24(18):3946-52. PubMed ID: 16564115
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
